Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep MedicineFallon Community Health Plan PAP Coverage Update |…
    Ask Trek AI about this page
    ModifiedFallon Community Health Plan IncPolicy SLP022022

    Treatment of Sleep Disordered Breathing in Adults and Children

    Customize your policy alerts

    Sign up for fallon_community_health_plan_inc Policy SLP022022 alerts

    Get alerted when Policy SLP022022 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical guideline for coverage and medical necessity criteria for positive airway pressure (PAP) therapies (CPAP, APAP, bi-level, ASV) for adults and children with sleep-disordered breathing; intended for Fallon Community Health Plan providers and claim reviewers.

    Policy Summary
    PayerFallon Community Health Plan Inc
    PolicyTreatment of Sleep Disordered Breathing in Adults and Children
    Policy CodePolicy SLP022022
    Change TypeClarified requalification pathwaydefinitions updatededitorial and reference updates
    Effective DateAug 1, 2026
    Next Review DateJun 1, 2027
    Key ActionDocument objective adherence (≥4 hrs/night on 70% of nights during a consecutive 30-day period within days 31–91) or obtain required face-to-face reevaluation to requalify after a failed 3-month PAP trial.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added clarifying language that members who fail the initial 3-month PAP trial, including due to nonadherence, are eligible to requalify for therapy following a face-to-face clinical reevaluation to determine the etiology of treatment failure.

    Clarified criteria language by adding 'AND' after Number 3 of Criterion A on page 3 to reduce ambiguity.

    Added definition for Severe COPD and clarified classification changes referring to Severe COPD.

    Updated references (2021-2026) and removed duplicates to align with the treatment-focused scope of the policy.

    90 daysinitial trial
    ≥4 hrs/nightadherence threshold
    5 yearsreplacement age
    Annualreview cycle
    AHI ≥15diagnostic threshold

    Coverage and Medical Necessity Criteria

    Initial CPAP/APAP therapy for adult OSA

    Covered when ANY of the following diagnostic conditions are met:

    Adult OSA diagnostic criteria: AHI, RDI, or REI ≥ 15 events/hourAHI/RDI/REI >= 15

    Applicable to adults, symptomatic or asymptomatic; requires positive PSG or HSAT

    Adult OSA alternative criteria: AHI, RDI, or REI 5–14 events/hour AND at least one qualifying comorbidity or symptomAHI/RDI/REI 5-14 plus ≥1 of: history of stroke, hypertension, ischemic heart disease, symptoms of impaired cognition/mood/insomnia, or excessive daytime sleepiness

    Meets medical necessity for an initial 90-day PAP trial

    Initial CPAP/APAP therapy for pediatric OSA

    Covered when ALL of the following are met:

    Pediatric PAP criteria: 1) OSA diagnosis established by diagnostic sleep test; 2) child weighs ≥30 kg (66 lb); 3) adenotonsillectomy unsuccessful or contraindicated, or definitive surgery must await complete dental/facial developmentsee text

    Initial 90-day CPAP/APAP trial considered medically necessary for eligible children

    Initial bi-level (E0470) for OSA

    Covered when ALL of the following are met:

    Bi-level for OSA: CPAP has been tried and proven ineffective or is not tolerated as documented by a qualified health professionaldocumented CPAP failure or intolerance

    Initial 90-day bi-level (E0470) trial is considered medically necessary when CPAP has failed or is not tolerated

    Bi-level (E0470/E0471) for other sleep disordered breathing (restrictive thoracic disease, severe COPD, CSA, hypoventilation)

    Covered when ALL specified physiologic and diagnostic criteria for each disorder are met (criteria vary by condition).

    Restrictive thoracic disorder: One of: awake PaCO2 ≥45 mm Hg on usual FiO2; sleep oximetry SpO2 ≤88% for ≥5 continuous minutes on usual FiO2; for progressive neuromuscular disease only, MIP <60 cm H2O or FVC <50% predictedsee text

    AND documentation that COPD does not contribute significantly to pulmonary limitation

    Severe COPD: A: awake PaCO2 ≥52 mm Hg on usual FiO2; B: sleep oximetry SpO2 ≤88% for ≥5 continuous minutes while on prescribed O2 or usual FiO2; C: prior CPAP tried/failed/not tolerated or ruled outsee text

    E0471 may be used after E0470 if PaCO2 rises ≥7 mm Hg or PSG on E0470 shows SpO2 ≤88% ≥5 cumulative minutes with AHI <5; continuation allowed up to 3 months post-hospital discharge for stabilization

    Central sleep apnea (CSA) / treatment-emergent CSA:

    Continued coverage beyond initial 90 days

    Covered when adherence/documentation requirements are met within days 31–91:

    OSA continued coverage adherence: Objective evidence of PAP use: ≥4 hours per night on 70% of nights during a consecutive 30-day period anytime during the first 3 months (day 31–91)≥4 hours/night on 70% of nights during any consecutive 30-day period between days 31 and 91

    If not met, continued coverage is considered not medically necessary

    Non-OSA bi-level continued coverage: Signed and dated statement by treating practitioner no sooner than 61 days after initiating device declaring average use of 4 hours per 24-hour period and that the member is benefiting from usephysician attestation after day 61

    If not met, continued coverage is considered not medically necessary

    Replacement and exclusions

    Covered replacements and exclusions:

    Device replacement coverage: Replacement is medically necessary with a prescription when the device is nonfunctioning and out of warranty or the device is greater than five years old; physician attestation acceptable if prior diagnostic test unavailabledevice nonfunctioning/out of warranty OR >5 years old

    Documentation may come from the physician or rendering provider

    Not medically necessary - duplicate/upgrade: Duplicate equipment for convenience (e.g., travel PAP) and replacement for the purpose of upgrading technology are not medically necessaryN/A

    PAP replacement and supply coverage

    Covered when ALL of the following are met

    Device replacement prescription and condition: Replacement of a PAP device or supplies is medically necessary with a prescription from a qualified health professional and confirmation that the device is nonfunctioning and out of warranty or is greater than five years olddevice >5 years OR nonfunctioning and out of warranty

    Documentation may come from the physician or rendering provider; physician attestation acceptable when prior diagnostic test unavailable

    Supply medical necessity: Accessories and supplies listed (masks, cushions, tubing, filters, humidifier parts, headgear, chinstrap) are medically necessary for members who meet PAP criteria; frequency of replacement should follow the PAP supply guidance tablesee PAP supply guidance (replacement frequencies vary by item)

    PAP cleaning machines/devices and certain cleaning methods (ozone, UV) are considered convenience and not covered

    Non-covered conveniences and alternative therapy considerations

    Duplicate equipment (for example, a travel PAP device) is considered a convenience and is not medically necessary

    Replacement for upgrading technology is not medically necessary

    Alternative nonsurgical therapies: Other nonsurgical therapies may be considered when PAP cannot be tolerated or an alternate is appropriate; coverage for oral appliances may be subject to the member's EPA or DME benefit terms

    Over-the-counter oral appliances obtained without a prescription are not medically necessary

    Experimental / investigational therapies

    The following OSA therapies are considered experimental and investigational or unproven

    Experimental therapies list: Sleep Strip; oral neuromuscular electrical stimulation devices (e.g., eXcite OSA); oral pressure therapy (e.g., Winx); Provent; atrial overdrive pacing; CAPSO; electrical positional therapy devices (e.g., Night Shift, Night Balance); Electrosleep therapy; Injection Snoreplasty; LAUP; over-the-counter non-customized mandibular appliances; Palatal Implant System; RFVTR (e.g., Coblation Somnoplasty); tongue-base suspension (e.g., AIRVance); transpalatal advancement pharyngoplasty; diaphragmatic-phrenic nerve stimulation for CSA

    These therapies are considered experimental/investigational or unproven and are not covered

    Requalification criteria

    Updates and eligibility clarifications

    Requalification after initial PAP failure: Members who fail the initial 3-month PAP trial, including due to nonadherence, are eligible to requalify for therapy following a face-to-face clinical reevaluation to determine the etiology of treatment failure.3-month trial

    Face-to-face clinical reevaluation required; documentation should capture the etiology of treatment failure and clinician assessment

    Treatment of isolated snoring alone, without evidence of obstructive sleep apnea on a diagnostic sleep study (PSG or HSAT), is not considered medically necessary. The policy explicitly states that if diagnostic criteria for OSA are not met, continued coverage of a PAP device and related accessories will be denied. Duplicate devices supplied solely for convenience (for example, a second "travel" PAP) are considered a convenience and are not medically necessary.

    Duplicate equipment (such as an additional travel PAP) and replacement of a PAP device for the purpose of upgrading technology are not medically necessary. Over-the-counter, non‑customized oral appliances obtained without a prescription are likewise not considered medically necessary. Replacement requests for devices or supplies must meet the policy's medical‑necessity replacement criteria (see replacement coverage), including documentation that the existing device is nonfunctioning/out of warranty or is >5 years old unless other policy exceptions apply.

    Prior guideline updates modified the policy's scope and specific lists: some items and tests formerly listed as experimental/investigational or as exclusions were moved or removed in earlier revisions. The update history documents clarifications to criteria language and addition of replacement-after-5-years language; however, the full policy contains the authoritative current exclusions and the detailed lists referenced in these update notes.

    An E0471 (bi‑level with backup rate) device is considered not medically necessary when the specific hypoventilation syndrome criteria referenced in the policy are not met. The policy permits escalation from E0470 to E0471 only when the documented physiologic and diagnostic escalation criteria are satisfied; absent those criteria, E0471 is not covered.

    PAP cleaning machines and marketed cleaning devices are treated as items of convenience and are not covered by the DME benefit when used for routine device cleaning; the policy specifically labels PAP cleaning machines and certain OTC cleaning methods as not covered. Similarly, over‑the‑counter oral appliances obtained without a prescription are not medically necessary and are excluded from coverage.

    Editorial and prior changes noted in the guideline history include insertion of clarifying language (for example, adding 'AND' to reduce ambiguity), addition of a 5‑year replacement allowance, and relocation or removal of certain items from experimental/ investigational lists. These editorial updates affect phrasing and where items appear in the full policy but do not alter the requirement that device replacement and coverage follow the medical‑necessity rules documented elsewhere in the policy.

    Codes, Diagnostic Thresholds, and Key Clinical Values

    Covered PAP device and humidifier codesHCPCSCovered
    E0601CPAP, APAP devices
    E0561Humidifier (heated) for CPAP/APAP
    E0562Humidifier (non-heated) for CPAP/APAP
    Covered bi-level device codesHCPCSCovered
    E0470Bi-level positive airway pressure device without backup rate
    E0471Bi-level positive airway pressure device with backup rate (ASV/auto SV)
    PAP supply HCPCS (masks, cushions, tubing, filters, humidifier parts)HCPCSCovered
    A4604TUBING WITH INTEGRATED HEATING ELEMENT FOR USE WITH POSITIVE AIRWAY PRESSURE DEVICE
    A7027COMBINATION ORAL/NASAL MASK, USED WITH CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE, EACH
    A7028ORAL CUSHION FOR COMBINATION ORAL/NASAL MASK, REPLACEMENT ONLY, EACH
    A7029NASAL PILLOWS FOR COMBINATION ORAL/NASAL MASK, REPLACEMENT ONLY, PAIR
    A7030FULL FACE MASK USED WITH POSITIVE AIRWAY PRESSURE DEVICE, EACH
    A7031FACE MASK INTERFACE, REPLACEMENT FOR FULL FACE MASK, EACH
    A7032CUSHION FOR USE ON NASAL MASK INTERFACE, REPLACEMENT ONLY, EACH
    A7033PILLOW FOR USE ON NASAL CANNULA TYPE INTERFACE, REPLACEMENT ONLY, PAIR
    A7034NASAL INTERFACE (MASK OR CANNULA TYPE) USED WITH POSITIVE AIRWAY PRESSURE DEVICE, WITH OR WITHOUT HEAD STRAP
    A7035HEADGEAR USED WITH POSITIVE AIRWAY PRESSURE DEVICE
    1–10 of 15
    1/2
    PAP and respiratory device HCPCSHCPCSCovered
    E0561Humidifier, non-heated, used with positive airway pressure device
    E0562Humidifier, heated, used with positive airway pressure device
    E0470Respiratory assist device, bi-level pressure capability, without backup rate feature
    E0471Respiratory assist device, bi-level pressure capability, with backup rate feature (describes adaptive servo ventilation)
    E0601CPAP (continuous positive airway pressure) device (also used for reporting APAP)
    Referenced CPT codesCPT
    95811Full-night attended polysomnography with positive airway pressure titration (referenced in update notes)
    Referenced proceduresmixed
    HSATHome Sleep Apnea Test (referenced as acceptable for some diagnostic criteria)
    inv-23: Adult OSA diagnostic threshold — AHI/RDI/REI ≥ 15 OR AHI 5–14 + comorbidity
    Adult diagnostic threshold (primary)AHI, RDI, or REI ≥ 15 events/hour (adult members, symptomatic or asymptomatic)
    Adult alternative thresholdAHI, RDI, or REI 5–14 events/hour plus at least one qualifying comorbidity or symptom (history of stroke, hypertension, ischemic heart disease, impaired cognition/mood/insomnia, or excessive daytime sleepiness)
    Acceptable test typesFacility-based polysomnogram (PSG) or Home Sleep Apnea Test (HSAT) meeting index definitions
    inv-24: Pediatric PAP eligibility — child diagnosed by sleep test, weight ≥30 kg, adenotonsillectomy unsuccessful/contraindicated or deferred
    Required diagnostic confirmation

    Prior Authorization, Documentation, and Operational Steps

    Prior Authorization

    Prior auth: Documentation of qualifying sleep test and criteria required

    Initial authorization for PAP devices (E0601, E0470, E0471) requires documentation of qualifying diagnostic sleep test results that meet the policy thresholds (adult AHI/RDI/REI ≥15, or 5–14 with at least one listed comorbidity/symptom) or the pediatric criteria; CPAP/APAP may include humidifier codes E0561 or E0562. If these diagnostic or eligibility criteria are not met, continued coverage will be denied.

    • Acceptable diagnostic tests: facility-based PSG or HSAT meeting the listed AHI/RDI/REI thresholds.
    • Adult thresholds: AHI/RDI/REI ≥15 OR AHI/RDI/REI 5–14 with ≥1 qualifying comorbidity/symptom.
    • Pediatric: diagnostic sleep test, weight ≥30 kg, and adenotonsillectomy unsuccessful/contraindicated or surgery deferred.
    • Humidifier support codes E0561/E0562 noted as applicable with CPAP/APAP.
    Prior Authorization

    Replacement authorization: prescription and device condition required

    Replacement devices and supplies require a prescription and confirmation that the device is nonfunctioning and out of warranty or is greater than five years old; documentation may be provided by the physician or rendering provider. If a prior diagnostic test is not available for a replacement request, a physician attestation supporting the diagnosis of OSA is acceptable.

    Clinical Background and Policy Context

    Obstructive sleep apnea (OSA) is commonly treated with positive airway pressure (PAP) devices. CPAP/APAP (E0601) provides continuous or auto‑adjusting positive airway pressure to maintain upper airway patency; humidifiers (E0561/E0562) may be used. Bi‑level devices (E0470/E0471) deliver separate inspiratory and expiratory pressures and are indicated when CPAP is ineffective or not tolerated or when specific physiologic criteria (for hypoventilation, severe COPD, or central sleep apnea) are met. Clinical follow‑up during an initial 90‑day trial and objective adherence assessment are required to determine continued medical necessity.

    Definitions and Device Classifications

    inv-47: CPAP/APAP (E0601) — continuous or auto-titrating positive airway pressure devices definition (low importance)
    DefinitionContinuous Positive Airway Pressure (CPAP) and Auto-Titrating Positive Airway Pressure (APAP) devices (HCPCS E0601) deliver fixed (CPAP) or auto-adjusting (APAP) airway pressure to maintain airway patency
    APAP behaviorAPAP varies pressure during treatment in response to physiologic measurements such as airflow or pressure fluctuations
    Typical useCPAP/APAP may be initiated in the home for members without significant comorbidities; close clinical follow-up is advised during initial weeks
    inv-48: Bi-level (E0470/E0471) — devices delivering different inspiratory and expiratory pressures; E0471 includes back-up rate (low importance)
    Bi-level without backup (E0470)Device delivers separate inspiratory and expiratory positive airway pressures to assist ventilation
    Policy Summary
    PayerFallon Community Health Plan Inc
    PolicyTreatment of Sleep Disordered Breathing in Adults and Children
    Policy CodePolicy SLP022022
    Change TypeClarified requalification pathwaydefinitions updatededitorial and reference updates
    Effective DateAug 1, 2026
    Next Review DateJun 1, 2027
    Key ActionDocument objective adherence (≥4 hrs/night on 70% of nights during a consecutive 30-day period within days 31–91) or obtain required face-to-face reevaluation to requalify after a failed 3-month PAP trial.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCodes, Diagnostic Thresholds, and Key Clinical ValuesPrior Authorization, Documentation, and Operational StepsClinical Background and Policy ContextDefinitions and Device Classifications
    Complete facility-based PSG documenting CSA or treatment-emergent CSA; CPAP ruled out if CSA or significant central component present; documentation of significant improvement with bi-level therapy on intended settings
    see text

    Consider device warnings and contraindications (e.g., ASV limitations in certain heart failure patients) when selecting E0471

    Hypoventilation syndrome: For E0470: A: awake PaCO2 ≥45 mm Hg on usual FiO2; B: FEV1/FVC ≥70% (when applicable); and either C: sleep PaCO2 increases ≥7 mm Hg versus awake ABG OR D: PSG/HSAT on CPAP/with prescribed FiO2 shows SpO2 ≤88% for ≥5 minutes with AHI <5see text

    E0471 covered only if E0470 ineffective and specified escalation criteria are met; otherwise E0471 is not medically necessary

    OSA diagnosis established by diagnostic sleep test
    Minimum weightChild must weigh ≥30 kilograms (66 pounds)
    Surgical status requirementAdenotonsillectomy has been unsuccessful or is contraindicated, or definitive surgery must await complete dental/facial development (surgery deferred)
    inv-25: Adherence threshold for continued coverage — Use ≥4 hrs/night on 70% of nights during a consecutive 30-day period within days 31–91
    Adherence metric (continued coverage)Objective evidence of PAP use ≥4 hours per night on 70% of nights during a consecutive 30-day period anytime between day 31 and day 91 after initiating therapy
    Documentation sourceObjective device-generated adherence report is required to demonstrate the above usage
    Consequence if not metIf objective adherence criterion is not met, continued coverage is considered not medically necessary
    inv-26: AHI severity thresholds (adults) — Mild/Moderate/Severe definitions
    Mild OSA (adults)AHI ≥5 and <15 events/hour
    Moderate OSA (adults)AHI ≥15 and <30 events/hour
    Severe OSA (adults)AHI ≥30 events/hour
    inv-27: Pediatric abnormal AHI — AHI ≥1
    Pediatric abnormal AHIAHI ≥1 events/hour is considered abnormal in pediatric members
    Index definitionAHI = total number of apneas plus hypopneas per hour of sleep
    Testing noteAHI interpretation should follow pediatric diagnostic sleep test standards
    inv-28: PAP compliance timeframe — Initial 3-month PAP trial (requalification pathway after failure)
    Initial trial durationInitial PAP trial is 3 months (90 days)
    Requalification pathway after failureMembers who fail the initial 3-month PAP trial (including for nonadherence) are eligible to requalify following a face-to-face clinical reevaluation to determine etiology of failure
    Documentation required for requalificationFace-to-face clinical reevaluation documentation by treating physician should capture etiology of treatment failure and clinician assessment
    • Replacement device considered medically necessary only when nonfunctioning & out of warranty OR >5 years old.
    • Prescription from a qualified health professional required for replacement.
    • Physician attestation is acceptable when prior diagnostic test is unavailable.
    Prior Authorization

    Prior auth criteria clarified; requalification after 3‑month failure requires face‑to‑face reevaluation

    The policy language for prior authorization and eligibility was clarified and now explicitly includes a requalification pathway: members who fail the initial 3‑month PAP trial (including for nonadherence) are eligible to requalify but must have a face‑to‑face clinical reevaluation to document the etiology of failure before reauthorization.

    • Follow updated criteria when requesting PAP replacement or re-initiation after initial trial failure.
    • Face-to-face clinical reevaluation required to determine etiology of treatment failure prior to requalification.
    Step Therapy

    Step therapy: E0470 required before E0471 unless escalation criteria met

    For bi-level therapy escalation, an E0470 (bi-level without backup) is required before requesting an E0471 (bi-level with backup) for many indications; E0471 is permitted when E0470 is ineffective or when the policy’s escalation criteria are met (e.g., PaCO2 increase ≥7 mm Hg or PSG evidence while on E0470).

    • Start with E0470 for OSA when CPAP has been tried and failed or is not tolerated.
    • E0471 may follow when documented E0470 failure/ineffectiveness and specified physiologic escalation criteria are satisfied.
    Note

    Therapy sequencing: PAP is first‑line; alternatives considered when PAP intolerable

    PAP is the preferred (gold‑standard) therapy for OSA; alternative nonsurgical therapies (e.g., oral appliances) may be considered only when PAP cannot be tolerated or an alternate is clinically appropriate and are subject to the member's EPA or DME benefit terms.

    • OTC oral appliances obtained without a prescription are not medically necessary.
    • Coverage for custom oral appliances depends on benefit terms and may require separate authorization.
    Prior Authorization

    Prior auth: follow updated/clarified criteria and documentation requirements

    Ensure prior authorization requests follow the updated criteria and clarified language effective with the policy revisions (including the requalification pathway and clarified criterion phrasing); use the most current documentation when requesting PAP replacement or re‑initiation.

    • Apply clarified wording (e.g., inserted 'AND' in specified criteria) and updated definitions (e.g., Severe COPD) when submitting requests.
    • Requests after initial trial failure must include face‑to‑face reevaluation documentation per the update.
    Documentation Required

    Documentation: submit sleep study, H&P, treatment plan, and physiologic tests as applicable

    Providers must submit diagnostic sleep study results, a physician history and physical, treatment plan/plan of treatment, and procedure notes when requesting initial coverage or replacement; for non‑OSA indications include physiologic testing (ABG, sleep oximetry, spirometry, PSG/HST) as applicable.

    • Required: PSG or HSAT results demonstrating policy thresholds, physician H&P, treatment plan, and procedure note.
    • For restrictive thoracic disease, severe COPD, CSA, or hypoventilation, include arterial blood gas, sleep oximetry, spirometry (FEV1/FVC), and facility PSG as appropriate.
    • Documentation for replacement may be a physician attestation if prior diagnostic test unavailable.
    Documentation Required

    Physiologic testing required for non‑OSA indications (ABG, oximetry, spirometry, PSG/HST)

    Physiologic testing is required to support non‑OSA bi‑level indications: include arterial blood gas results, sleep oximetry, spirometry (FEV1/FVC), and facility PSG/HST results as appropriate per the specific disorder criteria.

    • Restrictive thoracic disorder: awake PaCO2 ≥45 mm Hg OR sleep oximetry ≤88% ≥5 continuous minutes OR disease‑specific respiratory muscle testing.
    • Severe COPD and hypoventilation criteria specify awake PaCO2 thresholds and PSG/sleep oximetry findings as detailed in the policy.
    Documentation Required

    Adherence documentation required for continued coverage (≥4 hrs/night on 70% nights during days 31–91)

    To maintain coverage beyond the initial 90‑day trial, providers must document objective adherence: device‑downloaded evidence showing ≥4 hours/night on 70% of nights during any consecutive 30‑day period between day 31 and day 91; failure to meet this adherence may result in discontinuation of coverage.

    • Adherence window: no sooner than day 31 and no later than day 91 after therapy initiation.
    • Objective adherence definition: ≥4 hours/night on 70% of nights during a consecutive 30‑day period.
    Billing Rule

    Billing/documentation: submit H&P, procedure note, treatment plan, and sleep study; excess services subject to review

    Provide the policy‑listed required documentation to support medical necessity for reimbursement: physician history & physical, physician procedure note, treatment plan/plan of treatment, and sleep study results (PSG or HSAT as appropriate). Services exceeding policy‑documented scope are subject to medical review.

    • Include supporting sleep study and clinical notes with prior auth and claims.
    • Medical review may request additional records when services exceed what policy documents as medically necessary.
    Documentation Required

    Documentation: physician attestation acceptable for replacement when prior test unavailable

    Providers may submit a physician attestation to support a replacement device when the prior diagnostic test is unavailable; the attestation must support the diagnosis of OSA and accompanies the prescription for replacement.

    • Physician attestation accepted in lieu of prior diagnostic testing for replacement requests.
    • Replacement still requires prescription and confirmation device is nonfunctioning/out of warranty or >5 years old.
    Denial Risk

    Denial risk: insufficient objective adherence during days 31–91 may result in discontinuation

    If objective adherence criteria during days 31–91 are not met (i.e., member uses PAP <4 hours/night on <70% of nights during any consecutive 30‑day period), continued coverage may be discontinued per the policy.

    • Nonadherence identified in the 31–91 day window can lead to discontinuation of equipment and supply coverage.
    • For non‑OSA bi‑level indications, a signed dated clinician statement after 61 days documenting average use of 4 hours per 24‑hour period and benefit is required.
    Denial Risk

    Denial risk: E0471 not covered unless hypoventilation/COPD escalation criteria are satisfied

    An E0471 device (bi‑level with backup) is considered not medically necessary unless the policy’s specific hypoventilation or COPD escalation criteria are met (e.g., required PaCO2 thresholds, PSG/sleep oximetry evidence, or documented ineffective E0470 use).

    • E0471 coverage requires documented E0470 ineffectiveness and one of the policy’s escalation criteria (e.g., PaCO2 worsening ≥7 mm Hg or PSG showing SpO2 ≤88% ≥5 minutes while using E0470 with AHI <5).
    • If criteria are not met, E0471 is considered not medically necessary.
    Denial Risk

    Denial risk: duplicate equipment, convenience items, and upgrades not covered

    Services or items that are duplicate, for convenience (e.g., travel PAP), or intended solely to upgrade technology are not considered medically necessary and will not be covered.

    • Duplicate equipment (travel PAP) and replacement for upgrading technology are not medically necessary.
    • PAP cleaning machines and certain cleaning methods may be considered conveniences and not covered.
    Prior Authorization

    Requalification: face‑to‑face clinical reevaluation required after initial 3‑month PAP failure

    Face‑to‑face clinical reevaluation is required for members who failed the initial 3‑month PAP trial to requalify; documentation of the reevaluation should capture the etiology of treatment failure and clinician assessment.

    • Requalification eligibility follows failure (including nonadherence) of the initial 3‑month trial.
    • Document the in‑person clinical assessment and rationale for re‑initiating PAP therapy.
    Denial Risk

    Medical review risk: services must be supported by documentation in the medical record

    Providers must ensure documentation supporting all claims: if documentation in the record does not support services billed as medically necessary per the policy, those services are subject to medical review and potential denial.

    • Maintain sleep study reports, device adherence downloads, clinician notes, and prescriptions in the medical record.
    • Be prepared to submit records for medical review when requested.
    Note
    Bi-level with backup (E0471)
    Includes a back-up rate to deliver breaths if spontaneous breaths are not sensed within a preset interval
    Indications noteBi-level devices may improve comfort or effectiveness for some members with OSA and other respiratory conditions
    inv-49: Apnea — temporary cessation of breathing definition (low importance)
    Apnea definitionTemporary cessation of breathing with cessation of airflow for 10 seconds or more
    Clinical relevanceUsed in calculating indices of sleep disordered breathing (e.g., AHI)
    Associated physiologic effectLeads to interruption of oxygen intake and carbon dioxide release
    inv-50: Apnea-Hypopnea Index (AHI) — definition and notes about calculation (low importance)
    AHI definitionApnea-Hypopnea Index (AHI) = total number of apneas plus hypopneas per hour of sleep
    Calculation noteIf AHI is calculated from <2 hours of continuous recorded sleep, the total recorded events must be at least the number that would be required in 2 hours (≥10 events)
    UseAHI is an index of OSA severity used for diagnostic and coverage thresholds
    inv-51: Obstructive Sleep Apnea (OSA) — definition and adult severity categories (low importance)
    OSA definitionRepetitive apneas and/or hypopneas during sleep caused by collapse of the pharyngeal airway
    Adult severity categoriesMild: AHI ≥5–<15; Moderate: AHI ≥15–<30; Severe: AHI ≥30
    Pediatric notePediatric abnormal AHI is ≥1 events/hour
    inv-52: Severe COPD — definition added/clarified in Definitions to align coverage criteria (low importance)
    Severe COPD definition sourceSevere COPD is defined by GOLD criteria: GOLD 3 (FEV1 30%–50% predicted) and GOLD 4 (FEV1 <30% predicted)
    Purpose of inclusionDefinition was added/clarified in Definitions to align coverage criteria for bi-level therapy
    Reference noteClassification aligns with Global Initiative for Obstructive Lung Disease (GOLD) criteria